To the Editor The use of inhaled nitric oxide (iNO) in premature infants has remained one of the most controversial topics in neonatology. The consensus statement from the National Institutes of Health and the Clinical Report from the American Academy of Pediatrics have recommended against the use of iNO in premature neonates.1,2 The National Institutes of Health guidelines do point out that preterm infants with pulmonary hypoplasia (PH) and pulmonary hypertension may potentially benefit from this therapy.3 With loss of equipoise among neonatologists, it may be difficult to conduct a randomized clinical trial. Large databases and registries offer valuable information in the absence of randomized clinical trials.
Chandrasekharan P, Manja V, Lakshminrusimha S. Potential Benefits of Inhaled Nitric Oxide in Pulmonary Hypoplasia in Premature Neonates. JAMA Pediatr. 2018;172(11):1102–1103. doi:10.1001/jamapediatrics.2018.2892
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: